Lenalidomide and Rituximab for the Initial Treatment of Patients With Chronic Lymphocytic Leukemia: A Multicenter Clinical-Translational Study From the Chronic Lymphocytic Leukemia Research Consortium

PURPOSE: Lenalidomide is an immunomodulatory agent with therapeutic activity in chronic lymphocytic leukemia (CLL). In preclinical models, lenalidomide acted synergistically with rituximab. The CLL Research Consortium initiated a phase II study to evaluate this combination in treatment-naive patient...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: James, Danelle F., Werner, Lillian, Brown, Jennifer R., Wierda, William G., Barrientos, Jacqueline C., Castro, Januario E., Greaves, Andrew, Johnson, Amy J., Rassenti, Laura Z., Rai, Kanti R., Neuberg, Donna, Kipps, Thomas J.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2014
Matèries:
ORIGINAL REPORTS
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4067945/
https://ncbi.nlm.nih.gov/pubmed/24868031
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2013.51.5890
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars